BridgeBio Pharma Total Current Assets 2018-2024 | BBIO

BridgeBio Pharma total current assets from 2018 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
BridgeBio Pharma Annual Total Current Assets
(Millions of US $)
2023 $478
2022 $549
2021 $889
2020 $643
2019 $569
2018 $445
2017 $
BridgeBio Pharma Quarterly Total Current Assets
(Millions of US $)
2024-06-30 $616
2024-03-31 $783
2023-12-31 $478
2023-09-30 $588
2023-06-30 $433
2023-03-31 $553
2022-12-31 $549
2022-09-30 $642
2022-06-30 $771
2022-03-31 $716
2021-12-31 $889
2021-09-30 $640
2021-06-30 $910
2021-03-31 $945
2020-12-31 $643
2020-09-30 $745
2020-06-30 $862
2020-03-31 $925
2019-12-31 $569
2019-09-30 $558
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.911B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00